دورية أكاديمية
The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
| العنوان: | The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. |
|---|---|
| المؤلفون: | de Jong C; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, the Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands., Chargi N; Department of Head and Neck Surgical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht, Utrecht, the Netherlands., Herder GJM; Department of Pulmonology, Meander Medical Center, Amersfoort, the Netherlands., van Haarlem SWA; Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands., van der Meer F; Department of Pulmonology, Diakonessenhuis, Utrecht, the Netherlands., van Lindert ASR; Department of Pulmonology, University Medical Center Utrecht, Utrecht, the Netherlands., Ten Heuvel A; Department of Pulmonology, Groene Hart Hospital, Gouda, the Netherlands., Brouwer J; Department of Pulmonology, Rivierenland Hospital, Tiel, the Netherlands., de Jong PA; Department of Radiology, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Huitema ADR; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands.; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Egberts TCG; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands., de Bree R; Department of Head and Neck Surgical Oncology, Division of Imaging and Oncology Center, University Medical Center Utrecht, Utrecht, the Netherlands., Deneer VHM; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands. |
| المصدر: | Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2022 Jun; Vol. 13 (3), pp. 1554-1564. Date of Electronic Publication: 2022 Mar 18. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-6009 (Electronic) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Berlin : John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Original Publication: Heidelburg : Springer-Verlag |
| مواضيع طبية MeSH: | Antineoplastic Agents*/adverse effects , Carcinoma, Non-Small-Cell Lung*/complications , Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/complications , Lung Neoplasms*/drug therapy, Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Muscle, Skeletal/diagnostic imaging ; Prospective Studies |
| مستخلص: | Background: Chemotherapy-induced toxicities frequently occur in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Low skeletal muscle mass (SMM) has been associated with a higher incidence of toxicities for several types of cancers and cytostatics. The aim of this study was to evaluate the association between skeletal muscle measures and chemotherapy-induced toxicity in a large cohort of NSCLC patients. Methods: A multicentre prospective follow-up study (PGxLUNG, NTR number NL5373610015) in NSCLC patients was conducted. Included were patients diagnosed with NSCLC (stage II-IV) treated with first-line platinum-based (cisplatin or carboplatin) chemotherapy of whom pretreatment imaging was available. Skeletal muscle area (SMA) segmentation was performed on abdominal imaging at the level of the third lumbar vertebra (L3). SMA at the level of L3 was corrected for squared height (m 2 ) to yield the lumbar skeletal muscle mass index (LSMI). Skeletal muscle density (SMD) was calculated as the mean Hounsfield Unit (HU) of the segmented SMA. SMM and SMD were categorized as low, intermediate, and high, based on LSMI and mean HU tertiles, respectively. Chemotherapy-induced toxicity was scored using CTCAE v4.03 and categorized into haematological (anaemia, leukocytopenia, neutropenia, and thrombocytopenia), non-haematological (nephrotoxicity, neurotoxicity, and esophagitis), and dose-limiting toxicity (DLT) (treatment switch, delay, de-escalation, discontinuation, or hospitalization). The relationship between SMM, SMD, and toxicities was assessed with logistic regression modelling taking into account potential confounders like gender and body mass index (BMI). Results: In total, 297 patients (male n = 167, median age 64 years) were included. Haematological toxicity grade 3/4 was experienced in 36.6% (n = 108) of the patients, 24.6% (n = 73) experienced any non-haematological toxicity grade ≥2, and 55.6% (n = 165) any DLT. Multivariate logistic regression analysis showed that low SMM (ORadj 2.41, 95% CI 1.31-4.45, P = 0.005) and age at diagnosis >65 years (ORadj 1.76, 95% CI 1.07-2.90, P = 0.025) were statistically significantly associated with overall haematological toxicity grade 3/4. No statistically significant associations were found between low SMM or low SMD and non-haematological toxicities. Low SMM (ORadj 2.23, 95% CI 1.23-4.04, P = 0.008) and high SMD (ORadj 0.41, 95% CI 0.23-0.74, P = 0.003) were statistically significantly associated with a higher respectively lower risk of DLT. Conclusions: Non-small cell lung cancer patients with pretreatment low SMM are at significant higher risk for haematological toxicities grade 3/4 and DLT. NSCLC patients with high SMD are at significant lower risk for DLT. Further studies should be aimed to investigate whether platinum dosing based on skeletal muscle measurements and/or improvement of pretreatment SMM/SMD could reduce the risk of toxicity without compromising efficacy. (© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.) |
| References: | J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1554-1564. (PMID: 35301821) J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261. (PMID: 34904399) Chest. 2019 Jul;156(1):101-111. (PMID: 31128115) Lung Cancer. 2019 Jul;133:130-135. (PMID: 31200819) J Clin Med. 2020 Nov 23;9(11):. (PMID: 33238530) J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1283-1290. (PMID: 32725772) J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):803-813. (PMID: 31094083) Pharmaceuticals (Basel). 2021 Jan 09;14(1):. (PMID: 33435449) Front Oncol. 2021 May 07;11:580806. (PMID: 34026597) Thorac Cancer. 2020 Dec;11(12):3634-3640. (PMID: 33073546) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) J Geriatr Oncol. 2018 Jan;9(1):68-73. (PMID: 28844849) Clin Nutr. 2018 Oct;37(5):1707-1714. (PMID: 28743427) J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686) Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009) Oncologist. 2020 Mar;25(3):e555-e569. (PMID: 32162811) Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3. (PMID: 2520314) Br J Cancer. 2001 Nov 30;85(11):1634-9. (PMID: 11742480) Anticancer Res. 2019 Sep;39(9):4603-4612. (PMID: 31519557) Eur Arch Otorhinolaryngol. 2022 Feb;279(2):967-977. (PMID: 33956205) Interact Cardiovasc Thorac Surg. 2019 Jul 1;29(1):144-147. (PMID: 30843065) Cancer Med. 2016 Apr;5(4):607-16. (PMID: 26814378) Am J Kidney Dis. 2010 Apr;55(4):622-7. (PMID: 20338463) J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716) Support Care Cancer. 2016 Nov;24(11):4495-502. (PMID: 27236439) J Appl Physiol (1985). 2004 Dec;97(6):2333-8. (PMID: 15310748) Cancer Med. 2021 Jul;10(14):4781-4789. (PMID: 34121365) Acta Physiol (Oxf). 2014 Mar;210(3):489-97. (PMID: 24393306) J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):145-159. (PMID: 31536685) Clin Lung Cancer. 2017 Mar;18(2):e129-e136. (PMID: 27825639) Gen Thorac Cardiovasc Surg. 2019 Nov;67(11):949-954. (PMID: 30972530) J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1060-1069. (PMID: 31134765) J Thorac Dis. 2021 Feb;13(2):754-761. (PMID: 33717547) Toxicol Appl Pharmacol. 2014 Jul 15;278(2):190-9. (PMID: 24823295) Lancet Oncol. 2008 Jul;9(7):629-35. (PMID: 18539529) Cancer Manag Res. 2019 Apr 01;11:2579-2588. (PMID: 31114324) N Engl J Med. 2004 Jan 22;350(4):379-92. (PMID: 14736930) Br J Cancer. 2003 Sep 15;89(6):1022-7. (PMID: 12966419) Sci Rep. 2021 May 20;11(1):10628. (PMID: 34017035) Int J Mol Sci. 2020 Feb 13;21(4):. (PMID: 32069876) |
| معلومات مُعتمدة: | Roche Nederland B.V.; St. Antonius Onderzoeksfonds |
| فهرسة مساهمة: | Keywords: Body composition; Chemotherapy-induced toxicity; Non-small cell lung cancer; Platinum-based chemotherapy; Skeletal muscle mass |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20220318 Date Completed: 20220610 Latest Revision: 20230916 |
| رمز التحديث: | 20230916 |
| مُعرف محوري في PubMed: | PMC9178405 |
| DOI: | 10.1002/jcsm.12967 |
| PMID: | 35301821 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!